Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19

Angliana Chouw1,2 · Tiana Milanda3 · Cynthia Retna Sartika2 · Marsya Nilam Kirana2 · Danny Halim4 · Ahmad Faried4

Received: 15 December 2020 / Revised: 6 February 2021 / Accepted: 11 February 2021
© The Regenerative Engineering Society 2021

Abstract

The COVID-19 disease, which is caused by the novel coronavirus, SARS-CoV-2, has affected the world by increasing the mortality rate in 2020. Currently, there is no definite treatment for COVID-19 patients. Several clinical trials have been proposed to overcome this disease and many are still under investigation. In this review, we will be focusing on the potency of mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. Fever, cough, headache, dizziness, and fatigue are the common clinical manifestations in COVID-19 patients. In mild and severe cases, cytokines are released hyperactively which causes a cytokine storm leading to acute respiratory distress syndrome (ARDS). In order to maintain the lung microenvironment in COVID-19 patients, MSCs are used as cell-based therapy approaches as they can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote endogenous repair. Besides, MSCs have shown minimal expression of ACE2 or TMPRSS2, and hence, MSCs are free from SARS-CoV-2 infection. Numerous clinical studies have started worldwide and demonstrated that MSCs have great potential for ARDS treatment in COVID-19 patients. Preliminary data have shown that MSCs and MSC-derived secretome appear to be promising in the treatment of COVID-19.

Lay Summary

The COVID-19 disease is an infection disease which affects the world in 2020. Currently, there is no definite treatment for COVID-19 patients. However, several clinical trials have been proposed to overcome this disease and one of them is using mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. During the infection, cytokines are released hyperactively which causes a cytokine storm. MSCs play an important role in maintaining the lung microenvironment in COVID-19 patients. They can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote the endogenous repair. Therefore, it is important to explore the clinical trial in the world for treating the COVID-19 disease using MSCs and MSC-derived secretome.

Keywords COVID-19 · SAR-CoV-2 · Mesenchymal stem cell · Secretome · Exosome · Clinical trial

Introduction

In early 2020, the world was horrified by a severe acute atypical respiratory syndrome caused by viral respiratory diseases. The World Health Organization (WHO) office in China received the first report in late December 2019 that several patients in Wuhan, Hubei Province, were diagnosed with pneumonia of unknown cause. Later on, the causative agent was identified using sequencing technology as the novel coronavirus [1]. This novel coronavirus was originally called 2019-nCoV and later renamed officially as SARS-CoV-2 by the International Committee on Taxonomy of Viruses. This virus
causes the disease called COVID-19 that has affected not only China but also worldwide.

The estimated mortality rate of the disease is up to 5% with confirmed infected cases increasing daily [2]. Currently, there is no definite treatment for COVID-19; however, clinical trials have been performed using potential antimicrobials, immunoglobulin- or antibody-based therapy, and cell-based therapy [3–6]. The use of stem cell therapy has shown a promising impact in treating various diseases including degenerative and genetic disorders [7]. Therefore, in this review, we will discuss the potency of mesenchymal stem cells (MSCs) and MSC-derived secretome for COVID-19 treatment.

**Coronavirus Disease 2019**

Coronavirus disease 2019 (COVID-19) is a highly transmissible severe acute respiratory syndrome caused by SARS-CoV-2, an enveloped, single-stranded RNA virus belonging to the family Coronaviridae [8], alongside Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV), which broke out in 2012 and 2001, respectively. SARS-CoV-2 was reported to be a member of the β group of coronaviruses, Nidovirales order [9]. The homology of SARS-CoV-2 with SARS-CoV is up to 79.6% which was confirmed by full-length viral genome sequences [5, 10–12].

The possibility of animal to human transmission has been proven in previous outbreaks of SARS-CoV and MERS-CoV [13]. Several reports stated that the bat acts as the natural host for SARS-CoV-2 [12, 14], but the direct transmission to humans is unlikely to happen because of the differences in the habitats between them. A further study should be conducted to identify the intermediate host which transfers the infection from the bat to humans [15]. The virus spreads from human to human through droplets and aerosol transmission. A close contact with confirmed infected patients could increase the virus transmission, especially when they talk, cough, or sneeze [16, 17]. In combating the COVID-19, WHO and many countries have issued regulations such as social distancing and the use of masks in public areas [18]. Still, an indirect transmission when people touch an object and then touch their faces in particular their nose, mouth, or eyes might allow the virus to enter their body [19]. Moreover, it has been reported that SARS-CoV-2 could also spread through airborne transmission [20].

The clinical manifestations of a person who gets infected with SARS-CoV-2 are remarkably varied and include fever, cough, headache, dizziness, and fatigue. Other symptoms also include diarrhea. Coughing, breathing difficulties, dyspnea, and pneumonia are the respiratory problems that lead to acute respiratory distress syndrome (ARDS) [12, 13]. The development of ARDS in COVID-19 patients could progress rapidly resulting in high mortality rate [11]. The severity of COVID-19 patients was divided into 5 categories shown in Table 1.

**Mechanism of SARS-CoV-2 Invasion**

The invasion of the virus into the host cells involves the process of attachment, penetration, biosynthesis, maturation, and release. This mechanism also takes place in the SARS-CoV-2 invasion. There are 4 structural proteins in coronaviruses: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins [23, 24]. The spike protein located on the surface of the virus has two subunits: the S1 subunit binds to the host cell receptor in the process of attachment and the S2 subunit functions in the penetration activity, which allows the virus to enter the host cell through membrane fusion or endocytosis [25, 26]. Biosynthesis takes place after the virus released its genetic materials and the RNA enters the nucleus for replication. Once the maturation process is completed, a new virion is released. Similar to SARS-CoV, the angiotensin-converting enzyme 2 (ACE2) receptor was identified as the receptor of SARS-CoV-2 [11, 27]. The ACE2 receptor is reported to be distributed on the surface of endothelial cells and alveolar epithelial type II cells; therefore, SARS-CoV-2 could infect the cell with the ACE2 receptor [21]. Others also reported that the type 2 transmembrane serine 2 protease (TMPRSS2) and dipeptidyl peptidase IV (DPP-4) proteins act as the entry site of the virus [12]. SARS-CoV-2 attacks the lungs because the alveolar type II cells and the capillary endothelial cells express the ACE2 receptor and TMPRSS2 [28].

The infection will occur when the virions are released into the host’s body and spread to other cells. The antigen-presenting cells (APCs) will recognize the virus antigen and present it to the natural killer (NK) cell and CD8-positive cytotoxic T cells (CD8+ T cells). Both innate and adaptive immunity will be activated and produce pro-inflammatory cytokines and chemokines. However, in some cases, a massive uncontrolled immune response of the activated immune cells, lymphocytes, and macrophages could occur and might cause a cytokine storm. Overwhelming systemic inflammation, hypercytokinemia, and hyperferritinemia associated with multi-organ failure will appear in COVID-19 patients who experience the cytokine storm. Approximately, around 40% of the patients died due to ARDS-caused cytokine storms. In the event of a cytokine storm, pro-inflammatory cytokines such as interleukin (IL)-1, IL-1β, IL-6, IL-12, IL-18, IL-33, interferon (IFN)-α, IFN-γ, tumor necrosis factor (TNF)-α, and TNF-β along with chemokine (C-X-C motif) ligand (CXCL)10, CXCL8, CXCL9, CC chemokine ligand (CCL)2, and CCL5 increase (Fig. 1) [29–32].

Among all the pro-inflammatory cytokines, IL-6, and anti-inflammatory cytokine, IL-10 are reported to be the main factors in the cytokine storm [33]. During the cytokine storm,
granulocyte colony-stimulating factor (GCSF), IFN-gamma inducible protein (IP)-10, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory proteins (MIP)-1A, IL-2, and IL-7 are released which causes immune cell death and tissue damage resulting in clinical features such as edema, air exchange dysfunction, ARDS, and other secondary infections leading to death (Fig. 2) [31, 35, 36]. Lymphopenia is a common feature in COVID-19 patients with mild infection [37]. The CD4+ T cells, CD8+ T cells, B cells, and NK cells are decreased following the declining expression of IFN-γ in CD4+ T cells and upregulated NKG2A receptors on NK cells and CD8+ T cells [38, 39].

**Patient Management**

As there is no targeted therapy available until now, clinicians and researchers are mobilized to find the cure for COVID-19.

| Classification          | Symptoms                                                                 |
|-------------------------|--------------------------------------------------------------------------|
| Asymptomatic            | PCR tested positive without any clinical symptoms and signs. Chest imaging is normal |
| Mild                    | Symptoms of acute upper respiratory tract infection or digestive symptoms Cannot be detected by imaging procedures |
| Moderate/common         | Mild to high fever Pneumonia with no hyposmia Chest CT with lesion |
| Severe                  | Pneumonia with hyposxia (SpO2<92%) Respiration rate higher than 30/min Pressure of oxygen in arteries is less than 300 mmHg |
| Critical                | Acute respiratory distress syndrome (ARDS) Multiple organ failure May have shock, encephalopathy, myocardial injury, heart failure, coagulation dysfunction, and acute kidney injury |

**Fig. 1** The development of “cytokine storm” after SARS-CoV-2 infection due to the hyperactivation of immune cells
Clinical management of COVID-19 patients are currently only to control the infection progress and acts as supportive care. Oxygen and ventilator are used for treating COVID-19 patients when they need it [40]. Antimicrobial drugs such as lopinavir-ritonavir, remdesivir, ribavirin, favipiravir, hydroxychloroquine, corticosteroids, and azithromycin are also used for COVID-19 patients [41–43].

Several studies have shown that bone marrow, lymph nodes, thymus, spleen, and immune cells are negative for ACE2 suggesting the use of immunoglobulin for treating the patients [5, 44]. Antibody-based therapies using immunoglobulin, IL-6® monoclonal antibody, and convalescent plasma have also been tested in several clinical trials [45, 46]. Although the International Society for Stem Cell Research (ISSCR) has not approved stem cell–based approaches, many researchers have introduced MSCs for treating severe COVID-19 patients [4, 5].

**MSC Mechanism in COVID-19**

Cell-based therapy using stem cells, especially MSCs, also known as mesenchymal stromal cells and medicinal signaling cells, has become a promising tool in treating COVID-19 patients [47, 48]. MSCs are a promising candidate to treat COVID-19 because of the overreaction of the immune response. Hypothetically, MSCs act as the cell manager that re-activates the immune system to prevent the cytokine storm and promotes the endogenous repair [49, 50].

Long before COVID-19, MSCs have been used to treat immune and inflammatory diseases based on their potency as an immunomodulator [51]. The immunomodulatory activities include the proliferation inhibition of immune cells such as T cells, B cells, dendritic cells, and NK cells. The production of IL-10 is inhibited when the monocyte polarized into the anti-inflammatory M2 macrophages, leading to decreasing
production of TNF-α and IL-12 [5, 52]. MSCs also secrete anti-inflammatory molecules that reduce inflammation during injury [53].

After intravenous injection, the MSCs will be trapped in the lung. The secretion of a variety of soluble mediators such as growth factors, antimicrobial peptides, and extracellular vesicles by the MSCs will restore the pulmonary microenvironment resulting in the restoration of alveolar-capillary barriers, protection of alveolar epithelial cells, and interception of pulmonary fibrosis to cure dysfunction of the lung and COVID-19 pneumonia [54–56].

Different anti-inflammatory mediators are released into the lung microenvironment through different activation receptors. Toll-like receptors (TLRs) are activated by viral unmethylated CpG-DNA (TLR9) and viral RNA (TLR3), leading to a subsequent cellular signaling pathway. Growth factors such as keratinocyte growth factor (KGF) and angiopoietin-1 (Ang-1) promote the restoration of disrupted alveolar-capillary barriers [21, 22, 54]. In addition, MSCs also produce LL37, an antibiotic protein that neutralizes the SARS-CoV-2 [57]. A variety of paracrine factors that are secreted by MSCs interact with the immune cells in order to improve the condition of COVID-19 patients.

Some findings show that MSCs are resistant to viral infection compared to other differentiated cells. This is due to the presence of IFN-stimulated genes (ISG) which could block the virus from entering the cells. In addition, MSCs also express indoleamine 2,3-dioxygenase (IDO) that leads to the decrease of viral production [58]. Additionally, MSCs also promoted the regeneration of alveolar epithelial type II cells and prevented apoptosis through growth factors KGF, VEGF, and HGF [59].

The benefits of using MSCs in cell-based therapy are the easy way to obtain and free of ethical issues compared to embryonic stem cells [60]. In the MSC-based treatment of COVID-19 patients, MSCs were implicated to be free from SARS-CoV-2 infection because they minimally expressed ACE2 or TMPRSS2 receptors. This was proven by 10× RNA sequencing which shows that only 1 per 12,500 cells and 7 per 12,500 cells are expressed, respectively [22, 54]. Numerous clinical studies of MSC treatment for COVID-19 patients have begun worldwide and some publications have shown that MSCs are safe and have great potential for treating ARDS in COVID-19 patients. In one of the COVID-19 clinical trials, after the infusion of MSCs, the levels of C-reactive protein (CRP) in patients decreased while the number of peripheral lymphocytes increased [22, 61].

**MSC-Derived Secretome for COVID-19**

Other than orchestrating the cells to maintain and repair the injured tissue, MSCs also secrete multiple critical factors such as hormones and cytokines for tissue regeneration called secretome. During in vitro culture, MSCs secrete a complex mixture of soluble protein including exosomes, extracellular vesicles (EVs), cytokines, chemokines, and growth factors. This complex mixture is called the conditioned medium (CM). The CM emerges as a promising tool in cell-free therapy. Secretome shows immunomodulatory, anti-inflammatory, pro-angiogenic, and anti-protease properties similar to MSCs. Trophic factors such as tumor growth factor (TGF)-β, hepatocyte growth factor (HGF), leukemia inhibitory factor (LIF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), brain-derived neurotrophic factor (BDNF), and nerve growth factor (NGF) are also secreted by MSCs [52, 62].

As an immunomodulator, the PGE2, TGF-β, and HGF play roles in inhibition of dendritic cell maturation. PGE2 induces the elevation of IL-10, an anti-inflammatory factor, which inhibits the activation of CD4+ T cells and upregulates the Treg population [63]. Other growth factors such as VEGF and TGF-β are important to promote angiogenesis by activating the PI3K/Akt and MAPK pathways. The HGF and KGF are used for alveolar epithelial cell protection from apoptosis. The IGF-1 and IL-6 also elevated the secreted frizzled-related protein 2 (SFRP2) as an anti-apoptotic mediator [64].

As reported in a previous study, intravenous injection of secretome is distributed to the lungs and remains stable in the body [65]. Moreover, using secretome has its advantages compared to MSCs themselves especially in COVID-19 emergency because it has already been prepared before and could be used as ready-to-use products. The MSC-derived secretome has an advantage in storage conditions such as stability and lower cost compared to MSCs [66]. The MSC-derived secretome can activate the endogenous stem cells and progenitor cells, regulate the inflammatory response, stimulate angiogenesis and remodeling of the extracellular matrix, suppress apoptosis, mediate chemoattraction, and reduce fibrosis [4]. The MSC-derived secretome approach also avoids the risk of teratoma formation [67].

**MSC-Based Clinical Trials for COVID-19**

The first clinical trial using MSCs for treating COVID-19 in China evaluates the efficacy and safety of MSCs. Clinical trials registered through http://www.clinicaltrials.gov showed different approaches in treating COVID-19. Until July 2020, using the terms “COVID-19” and “mesenchymal stem cells”, we found 42 clinical trials of MSCs for COVID-19, most of them are in the recruiting of participant phase and several clinical trials that have been FDA-approved are ongoing at present. Although most of the clinical trials were conducted in China, other countries such as Brazil, Mexico, Pakistan, Spain, Belarus, Jordan, Iran, Colombia, Germany, Ukraine,
| Principal investigator, year | Clinical trial number | Title | Number of sample (patient) | Intervention | Dosage | Route of administration | Booster Study location |
|-----------------------------|-----------------------|-------|-----------------------------|--------------|--------|-------------------------|-----------------------|
| Lei Shi & Fu-Sheng Wang, 2020 | NCT04252118 | Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus | 20 patients: - treated group - control group | MSC | $3.0 \times 10^7$ cells | Intravenous | 3 times: - Day 1 - Day 4 - Day 7 China |
| XingHuan Wang & ZhiYong Peng, 2020 | NCT04269525 | Umbilical Cord (UC)-Derived Mesenchymal Stem Cells (MSCs) Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia | 16 patients | UC-MSC | $1.0 \times 10^3$ MSC in 150 mL | Intravenous | 4 times: - Day 1 - Day 3 - Day 5 - Day 7 China |
| Yang Jin, 2020 | NCT04273646 | Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia | 48 patients: - treated group - placebo group | UC-MSC | $0.5 \times 10^6$ kgBW in NaCl + 1% albumin | Intravenous | 4 times: - Day 1 - Day 3 - Day 5 - Day 7 China |
| Jie-ming Qu, 2020 | NCT04276987 | A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia | 30 patients | MSC-derived exosome | $2.0 \times 10^8$ nano vesicles/3 ml | Aerosol inhalation | 5 times: - Day 1 - Day 2 - Day 3 - Day 4 - Day 7 China |
| Fu-Sheng Wang, 2020 | NCT04288102 | Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19) | 100 patients: - treated group - placebo group | UC-MSC | $4.0 \times 10^6$ in NaCl containing 1% human serum albumin | Intravenous | 3 times: - Day 1 - Day 4 - Day 7 China |
| Yang Jin, 2020 | NCT04273646 | Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia | 48 patients: - treated group - placebo group | UC-MSC | $0.5 \times 10^6$ UC-MSCs/kg-BW | Intravenous | 4 times: - Day 1 - Day 3 - Day 5 - Day 7 China |
| Martin Iglesias & Carlos A Aguilar-Salinas, 2020 | NCT04416139 | Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19 (COVID-19) | 10 patients: - treated group - control group | MSC | $1.0 \times 10^6$ cells/kgBW | Intravenous | - Mexico |
| Xanab Akram, 2020 | NCT04444271 | Mesenchymal Stem Cell Infusion for COVID-19 Infection | 10 patients: - treated group - control group | MSC | $2.0 \times 10^6$ cells/kgBW | Intravenous | 2 times: - Day 1 - Day 7 Pakistan |
| Guillermo Sánchez-Vanegas & Carlos Escobar-Soto, 2020 | NCT04429763 | Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia (CELMA) | 30 patients: - treated group - control group | MSC | $1.0 \times 10^6$ cells/kgBW | Intravenous | - - |
| Ana Cardesa Gil, 2020 | NCT04366323 | Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19 | 26 patients | AD-MSC | $8.0 \times 10^7$ cells | Intravenous | 2 times: - Day 1 - Day 7 Spain |
| Jesus Perez, 2020 | NCT04456361 | Use of Mesenchymal Stem Cells in Acute Respiratory Distress | 9 patients | UC-MSC | $1.0 \times 10^8$ cells | Intravenous | - Mexico |
| Principal investigator, year | Clinical trial number | Title                                                                 | Number of sample (patient) | Intervention | Dosage               | Route of administration | Booster Study location |
|-----------------------------|-----------------------|----------------------------------------------------------------------|-----------------------------|--------------|----------------------|------------------------|------------------------|
| Florentino de Araujo Cardoso Filho & Luciana Ferrara, 2020 | NCT04315987           | Nestacell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia (HOPE) | 90 patients: treated group - control group | MSC - NestCell | $2.0 \times 10^7$ cells | Intravenous | 4 times: - Day 1 - Day 3 - Day 5 - Day 7 | Brazil                |
| Candy Eller, 2020           | NCT04428801           | Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19           | 200 patients: treated group - control group | AD-MSC       | $2.0 \times 10^8$ cells | Intravenous | 3 times: - Day 1 - Day 4 - Day 7 | -                     |
| Adeeb M AlZoubi & Ahmad Y AlGhadi, 2020 | NCT04313322           | Treatment of COVID-19 Patients Using Wharton’s Jelly-Mesenchymal Stem Cells | 5 patients                  | WJ-MSC       | $1.0 \times 10^6$ cells/kgBW | Intravenous | 3 times: - Day 1 - Day 2 - Day 3 | Jordan                |
| Ismail H Dilog & Tri Kurniawati, 2020 | NCT04457609           | Administration of Allogeneic UC-MSCs as Adjuvant Therapy for Critically-III COVID-19 Patients | 40 patients: treated group - control group | UC-MSC       | $1.0 \times 10^6$ cells/kgBW in 100 mL NaCl | Intravenous | - | Indonesia |
| Qingsong Ye & Chenliang Zhou, 2020 | NCT04336254           | Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients | 20 patients: treated group - control group | DP-MSC       | $3.0 \times 10^7$ cells in NaCl | Intravenous | 3 times: - Day 1 - Day 4 - Day 7 | China |
| Thanh Cheng, 2020           | NCT04349631           | A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia | 5 patients                  | AD-MSC       | -                     | Intravenous | - | USA |
| Yan Liu & Yue Zhu, 2020     | NCT04339660           | Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19) | 30 patients: treated group - control group | UC-MSC       | $1.0 \times 10^6$ cells/kgBW in 100 mL NaCl | Intravenous | - | China |
| Shiyue Li & Ming Liu, 2020  | NCT04346368           | Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19) | 20 patients: treated group - control group | BM-MSC       | $1.0 \times 10^6$ cells/kgBW | Intravenous | - | China |
| Thanh Cheng & Joseph Varon, 2020 | NCT04348435           | A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 | 100 patients: treated 1 group - treated 2 group - treated 3 group - placebo group | AD-MSC       | $0.5 \times 10^6$ cells - 1.0 $\times 10^6$ cells - 2.0 $\times 10^6$ cells | Intravenous | 5 times: - Week 0 - Week 2 - Week 6 - Week 10 - Week 14 | USA |
| Ryan Welter                 | NCT04352803           | Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease | 20 patients: treated group - control group | AD-MSC       | $5.0 \times 10^6$ cells/kgBW | Intravenous | - | - |
| Principal investigator, year | Clinical trial number | Title | Number of sample (patient) | Intervention | Dosage | Route of administration | Booster Study location |
|-----------------------------|-----------------------|-------|---------------------------|--------------|--------|-------------------------|----------------------|
| Camillo Ricordi, 2020       | NCT04355728           | Use of UC-MSCs for COVID-19 Patients | 24 patients: treated group - placebo group | UC-MSC       | $1.0 \times 10^6$ cell | Intravenous            | 2 times: - Day 1 - Day 4 USA |
| Masoumeh Nouri & Hoda Madani, 2020 | NCT04366063 | Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome | 60 patients: treated 1 group - treated 2 group - control group | MSC - MSC & EV | $1.0 \times 10^6$ cell | Intravenous            | MSC - 2 times: - Day 1 - Day 3 EV - 2 times: - Day 5 - Day 7 Iran |
| Vincent Liao, 2020          | NCT04452097           | Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS | 9 patients: treated 1 group - treated 2 group - control group | UC-MSC       | $0.5 \times 10^6$ cells/kgBW - $1.0 \times 10^6$ cells/kgBW - $1.5 \times 10^6$ cells/kgBW | Intravenous            | - |
| Jianming Tan Tan, 2020      | NCT04371601           | Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 | 60 patients: treated group - control group | UC-MSC       | $1.0 \times 10^6$ kgBW | Intravenous            | 4 times: - Day 1 - Day 4 - Day 8 - Day 12 China |
| Alfredo Hernandez-Ruiz & Santiago Saldarriaga-Gomez, 2020 | NCT04390152 | Safety and Efficacy of Intravenous Wharton’s Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID-19 | 40 patients: treated group - control group | WJ-MSC       | $5.0 \times 10^7$ cells | Intravenous            | 2 times Colombia |
| Annetine C Gelijns, 2020    | NCT04371393           | MSCs in COVID-19 ARDS | 300 patients: treated group - placebo group | MSC - Remestemcel-L | $2.0 \times 10^6$ cells/kgBW | Intravenous            | 2 times: - Day 1 - Day 5 USA |
| Katherine Ruppert & Sherry Diers, 2020 | NCT04362189 | Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 | 100 patients: treated group - placebo group | AD-MSC       | $1.0 \times 10^8$ cell | Intravenous            | 4 times: - Day 1 - Day 4 - Day 8 - Day 11 USA |
| Lennie Sender, 2020         | NCT04397796           | Study of the Safety of Therapeutic Tx With Immumonodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation | 45 patients: treated group - placebo group | BM-MSC       | -                  | Intravenous            | - |
| Peter Rosenberger, 2020     | NCT04377334           | Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS) | 40 patients: treated group - control group | BM-MSC       | -                  | Intravenous            | - Germany |
| Principal investigator, year | Clinical trial number | Title | Number of sample (patient) | Intervention | Dosage | Route of administration | Booster | Study location |
|-----------------------------|-----------------------|-------|---------------------------|--------------|--------|-------------------------|---------|----------------|
| Peter Nemtinov, 2020        | NCT04461925           | Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs | 30 patients: | UC-MSC | $1.0 \times 10^6$/kgBW | Intravenous | 3 times: | Ukraine |
| - treated group             | - control group       | |                           |              |        |                         | Day 1   |                |
| Liwei cheng, 2020           | NCT04302519           | Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells | 24 patients | DP-MSC | $1.0 \times 10^6$/kgBW | Intravenous | 3 times: | China |
| Ruth Coll & Joaquin Delgadillo, 2020 | NCT04390139 | Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19 (COVIDM15S) | 30 patients: | WJ-MSC | $1.0 \times 10^6$/kgBW | Intravenous | 2 times: | Spain |
| - treated group             | - placebo group       | |                           |              |        |                         | Day 1   |                |
| - control group             |                     | |                           |              |        |                         | Day 3   |                |
| Gokhan T Adas & Erdal Karaoz, 2020 | NCT04392778 | Clinical Use of Stem Cells for the Treatment of COVID-19 | 30 patients: | UC-MSC | $3.0 \times 10^6$/kgBW | Intravenous | 3 times: | Turkey |
| - treated group             | - placebo group       | |                           |              |        |                         | Day 1   |                |
| - control group             |                     | |                           |              |        |                         | Day 4   |                |
| - control group             |                     | |                           |              |        |                         | Day 7   |                |
| Barbara Juna & Mireia Arcas, 2020 | NCT04348461 | Battle Against COVID-19 Using Mesenchymal Stromal Cells | 100 patients: | AD-MSC | $1.5 \times 10^6$/kgBW | - | 2 times: | - |
| - treated group             | - placebo group       | |                           |              |        |                         | -       |                |
| Oscar Simonsson & Karl-Henrik Grinnemo, 2020 | NCT04447833 | Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome (ARDS-MSC-205) (REALIST) (COVID-19) (REALIST) | 9 patients: | BM-MSC | $-1.0 \times 10^6$/kgBW | - | - | Sweden |
| - treated 1 group           | - treated 2 group     | |                           |              |        |                         | -       |                |
| Danny F McAuley & Cecilia O’Kane, 2020 | NCT03042143 | Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19) (REALIST) | 75 patients: | UC-MSC | - | - | - | UK |
| - treated group             | - placebo group       | |                           |              |        |                         | -       |                |
| David Ingbar, 2020          | NCT04466098           | Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19) | 30 patients: | MSC | $3.0 \times 10^6$ in DMSO + dextran 40 + 5% human serum albumin | - | 3 times: | USA |
| - treated group             | - placebo group       | |                           |              |        |                         | Day 1   |                |
| - treated group             | - placebo group       | |                           |              |        |                         | Day 3   |                |
| - treated group             | - placebo group       | |                           |              |        |                         | Day 5   |                |
| Brian Miller, 2020          | NCT04445220           | A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy | 24 patients: | MSC | $-2.5 \times 10^6$ cells + SHAM device | - | - | - |
| - treated 1 group           | - treated 2 group     | |                           |              |        |                         | -       |                |
| - treated 2 group           | - placebo group       | |                           |              |        |                         | -       |                |
| - SHAM device               |                     | |                           |              |        |                         | -       |                |

AD-MSC adipose-derived mesenchymal stem cell, BM-MSC bone marrow–derived mesenchymal stem cell, DP-MSC dental pulp–derived mesenchymal stem cell, UC-MSC umbilical cord–derived mesenchymal stem cell, WJ-MSC Wharton jelly–derived mesenchymal stem cell
Turkey, Sweden, the USA, the UK, Denmark, and Indonesia are also executing the clinical trials (Table 2).

The study involves the different sources of MSCs, routes of administration, and also different approaches using cells or their secreted products. Based on the information of cell number use for clinical trial, the range of injected cells is between $0.5 \times 10^6$ and $1 \times 10^7$ cells/kg. Some studies proposed a single injection and others mention boosted therapy with an interval of 2–5 times. Intravenous, intratracheal, intraperitoneal, and intranasal injection methods are used for the route of administration of the MSCs or MSC-derived secretome. The most common source of MSCs that are used in the study is the allogeneic umbilical cord (UC)/Wharton’s jelly because of its non-invasive procedure to obtain and indicated more effective than other sources.

Similar to other clinical trials, a MSC study for COVID-19 involves a control group and a standard treatment for the patient. Other models also used a placebo, which means the standard treatment combination with normal saline as the intervention. The present data reveal that during short-term therapy, MSCs succeed in managing severe and critically severe COVID-19 patient condition and were reported to be safe and has shown efficacy. A study conducted by Leng et al. reported that 7 enrolled patients show positive outcomes 14 days after being injected with MSCs. Positive outcomes are shown by increasing oxygen saturation up to 95% at rest. Analysis of immune cells revealed that there is an increment of Tregs and dendritic cells with the disappearance of T and NK cells. Comparison between the control group and the MSC-treated group displayed that peripheral lymphocytes and levels of IL-10, IP-10, and VEGF rise while C-reactive protein and TNF-α decreased. A case report on a 65-year-old woman by Liang et al. showed no adverse event and patient improvement 4 days post-injection of $5.0 \times 10^7$ cells/administration UC-MSCs. However, in the long-term evaluation, a comparison between doses and routes of administration is needed to provide the best outcome for the patient [21, 68]. It is also important that the MSCs and MSC-derived secretome are produced in a good manufacturing practices (GMP) compliance facility to ensure the quality of the cell and eliminate the batch-to-batch variation [34].

Conclusion

MSCs and MSC-derived secretome displayed to be promising treatment candidates for COVID-19. Preliminary data from current clinical trials report that MSCs are safe and have efficacy. Nevertheless, much bigger data are needed for understanding the mechanism of MSCs and MSC-derived secretome for treating COVID-19 patients.

Declarations

Conflict of Interest The authors declare no competing interests.

References

1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74.
2. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669–77.
3. Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML, Corsico AG. Mesenchymal stromal cell secretome for severe COVID-19 infections: premises for the therapeutic use. Cells. 2020;9(4):924.
4. Deffune E, Prudenciatti A, Moroz A. Mesenchymal stem cell (MSC) secretome: a possible therapeutic strategy for intensive-care COVID-19 patients. Med Hypotheses. 2020;142:109769.
5. Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal stem cell therapy for COVID-19: present or future. Stem Cell Rev Rep. 2020;16(3):427–33.
6. Qu W, Wang Z, Hare JM, Bu G, Mallea JM, Pascual JM, et al. Cell-based therapy to reduce mortality from COVID-19: systematic review and meta-analysis of human studies on acute respiratory distress syndrome. Stem Cells Transl Med. 2020;9(9):1007–22.
7. Nawab K, Bheri D, Bommarito A, Mufti M, Naeem A. Stem cell therapies: a way to promising cures. Cureus. 2019;11(9):e5712.
8. Li H, Liu S-M, Yu X-H, Tang S-L, Tang C-K. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020;55(5):105951.
9. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91–8.
10. Kang S, Peng W, Zhu Y, Lu S, Zhou M, Lin W, et al. Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. Int J Antimicrob Agents. 2020;55(5):105950.
11. Yuki K, Fujisugi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol. 2020;215:108427.
12. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3.
13. Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 2020;56(2):106054.
14. Banerjee A, Kulochar K, Misra V, Frieman M, Mossman K. Bats and coronaviruses Viruses. 2019–2020;109:102433.
18. Howard J, Huang A, Li Z, Tufekci Z, Zdimal V, van der Westhuizen H-M, et al. An evidence review of face masks against COVID-19. Proc Natl Acad Sci USA. 2021;118(4):e2014564118.

19. Keni R, Alexander A, Nayak PG, Mugdal J, Nandakumar K. COVID-19: emergence, spread, possible treatments, and global burden. Front Public Health. 2020;8:216.

20. Sethi L, Passarini F, De Gennaro G, Barbieri P, Perrone MG, Borelli M, et al. Airborne transmission route of COVID-19: why 2 meters/6 feet of inter-personal distance could not be enough. Int J Environ Res Public Health. 2020;17(8):2932.

21. Rajarski J, Chatterjee A, Ray S. Combating COVID-19 with mesenchymal stem cell therapy. Biotechnol Rep (Amst). 2020;26: e00467.

22. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–28.

23. Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193–292.

24. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16(1):69.

25. Pandey P, Rane JS, Chatterjee A, Kumar A, Ray S, Prakash A, et al. Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development. J Biolom Struct Dyn. 2020;1–11.

26. Song P, Li W, Xie J, Hou Y, You C. Cytokine storm induced by SARS-CoV-2. Clin Chim Acta. 2020;509:280–7.

27. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102–8.

28. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80.

29. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–39.

30. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The molecular biology of coronaviruses. Adv Virus Res. 2020;7(S1):41.

31. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

32. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Saleem R. The COVID-19 cytokine storm: what we know so far. Front Immunol. 2020;11:1446.

33. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123–30.

34. Saldanha-Araujo F, Melgaço Garcez E, Silva-Carvalho AE, Carvalho JL. Mesenchymal stem cells: a new piece in the puzzle of COVID-19 treatment. Front Immunol. 2020;11:1563.

35. Conti P. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):1.

36. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393.

37. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20(5):269–70.

38. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). MedRxiv. 2020;PPR112622.
inflammatory lung diseases: current understanding and future perspectives. Stem Cells Int. 2019;2019:1–14.

60. Musiał-Wysocka A, Kot M, Majka M. The pros and cons of mesenchymal stem cell-based therapies. Cell Transplant. 2019;28(7):801–12.

61. Liang B, Chen J, Li T, Wu H, Yang W, Li Y, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells. Medicine. 2020;99(31):e21429.

62. Meiliana A, Dewi NM, Wijaya A. Mesenchymal stem cell secretome: cell-free therapeutic strategy in regenerative medicine. Indones Biomed J. 2019;11(2):113–24.

63. Mahajan A, Bhattacharyya S. Application of mesenchymal stem cell and secretome for combating mortality and morbidity in COVID-19 patients: a brief review. Biom J. 2020. https://doi.org/10/1016/j.bj.2020.090.003.

64. Sadeghi S, Soudi S, Shafiee A, Hashemi SM. Mesenchymal stem cell therapies for COVID-19: current status and mechanism of action. Life Sci. 2020;262:118493.

65. Hu S, Park J, Liu A, Lee J, Zhang X, Hao Q, et al. Mesenchymal stem cell microvesicles restore protein permeability across primary cultures of injured human lung microvascular endothelial cells: MSC-derived MVs stabilize lung endothelium. Stem Cells Transl Med. 2018;7(8):615–24.

66. Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci. 2017;18(9):1852.

67. Gomzikova MO, Rizvanov AA. Current trends in regenerative medicine: from cell to cell-free therapy. BioNanoSci. 2017;7(1):240–5.

68. Damayanti S, Triana R, Chouw A, Dewi NM. Is stem cell a curer or an obstruction? Mol Cell Biomed Sci. 2017;1(1):17.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.